Sepsis: the EMCD can save millions of patients worldwide with its efficient removal of all pathogens
in the bloodstream, preventing any sort of inflammation
HIV/AIDS: the EMCD will be able to bind to the HIV virus, reducing proliferation and progression to AIDS.
It also helps HIV/AIDS patients to survive pathogenic attacks even with their weak immune system
Immunodeficiency Disorders: people born with immunodeficiency disorders will have an easy, efficient,
and quick process to rid their blood of pathogens
Organ Transplants: the EMCD allows for the immunosuppressant to do its job without placing the patient at extreme risk
Other Bacterial and Viral Diseases: the EMCD quickly and completely removes the pathogens from the body
no need to identify the pathogen before treatment as MBLs can bind to a wide variety of pathogens and toxins
the EMCD completely eliminates the bacteria unlike antibiotic treatments, removing any debris to help reduce the over-excited inflammatory response
the EMCD does not contribute to antibiotic resistance
Sepsis is the most expensive medical condition. Hospitals in the United States spend over $20,000,000 annually to treat 1,600,000 million sepsis patients
Lifetime Antiretroviral Therapy (ART) for HIV/AIDS costs around $367,134 per person
The EMCD is a cheap solution to both, as the genetically modified MBLs comprise the majority of its cost.
However, the MBLs, like all other aspects of the EMCD, can easily be mass produced.
Genetically engineering MBLs could be costly and difficult to manufacture
May harm the Antiretroviral Therapy (ART) and antibiotic industries
Little to no environmental footprint after manufacturing